TLX591 (177Lu)
Prostate Cancer Therapy
Phase IIIActive (ProstACT Global)
Key Facts
Indication
Prostate Cancer Therapy
Phase
Phase III
Status
Active (ProstACT Global)
Company
About Telix Pharmaceuticals
Telix Pharmaceuticals is a leader in the radiopharmaceutical space, focused on delivering precision oncology through targeted radiation. The company has achieved commercial success with its prostate cancer imaging agent Illuccix® and is advancing a deep pipeline of theranostic candidates, including its pivotal Phase III therapy program for prostate cancer (ProstACT). With a global operational footprint, including a major manufacturing facility in Belgium, Telix is positioned to scale its innovative platform across multiple high-need cancer indications.
View full company profile